⌕
Arcturus Therapeutics Holdings · ARCT · Nasdaq
Tenet 61 · Solid
Compare
$8.31−0.60%At closeTenet 61 · Solid
$8.31−0.05 (−0.60%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Arcturus Therapeutics Holdings (ARCT) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is ARCT's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Business WireNov 16, 2026 · 08:30 ET
Arcturus Therapeutics Announces $50 Million Investment by Meiji Seika Pharma as Part of Expanded Collaboration

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeu…

ARCT −0.6% todayRead at source ↗
● Seeking AlphaNov 6, 2026 · 01:04 ET
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2026 Earnings Call Transcript

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2026 Earnings Call Transcript…

ARCT −0.6% todayRead at source ↗
● MarketBeatNov 5, 2026 · 22:17 ET
What Arcturus Therapeutics (ARCT) Said on Its Q3 Earnings Call

Arcturus Therapeutics NASDAQ: ARCT expects to complete enrollment in a mid-stage cystic fibrosis study by the end of 2026 and begin dosing a next-generation treatment for a rare liver disorder in the first quarter of 202…

ARCT −0.6% todayRead at source ↗
● Zacks Investment ResearchNov 5, 2026 · 18:45 ET
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $0.49 per share a year ago.…

ARCT −0.6% todayRead at source ↗
● Business WireNov 5, 2026 · 16:01 ET
Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeu…

ARCT −0.6% todayRead at source ↗
● Business WireOct 26, 2026 · 16:01 ET
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeu…

ARCT −0.6% todayRead at source ↗
● Zacks Investment ResearchSep 28, 2026 · 12:01 ET
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation

RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.…

ARCT −0.6% todayRead at source ↗
● MarketBeatSep 24, 2026 · 23:02 ET
Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform

Arcturus Therapeutics NASDAQ: ARCT presented preliminary Phase II data for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase, or OTC, deficiency, while outlining plans to introduce a next-generation…

ARCT −0.6% todayRead at source ↗
● Seeking AlphaSep 24, 2026 · 02:39 ET
Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform Transcript

Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform Transcript…

ARCT −0.6% todayRead at source ↗
● Business WireSep 23, 2026 · 16:01 ET
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeu…

ARCT −0.6% todayRead at source ↗
● Seeking AlphaSep 21, 2026 · 11:29 ET
Arcturus Therapeutics: A Speculative Buy For Their OTC Deficiency Program

Arcturus Therapeutics is advancing mRNA-based therapies, with ARCT-810 for OTC deficiency as a near-term catalyst and ARCT-032 for cystic fibrosis in phase 2. ARCT-810 has shown promising phase 2 interim data, normalizin…

ARCT −0.6% todayRead at source ↗
● Business WireSep 18, 2026 · 09:00 ET
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare dis…

ARCT −0.6% todayRead at source ↗
● Seeking AlphaSep 9, 2026 · 12:57 ET
Arcturus Therapeutics Holdings Inc. (ARCT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Arcturus Therapeutics Holdings Inc. (ARCT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript…

ARCT −0.6% todayRead at source ↗
● Defense WorldSep 4, 2026 · 04:12 ET
56,895 Shares in Arcturus Therapeutics Holdings Inc. $ARCT Bought by Hsbc Holdings PLC

Hsbc Holdings PLC acquired a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange…

ARCT −0.6% todayRead at source ↗
● Defense WorldSep 4, 2026 · 03:29 ET
BlackRock Inc. Invests $17.57 Million in Arcturus Therapeutics Holdings Inc. $ARCT

BlackRock Inc. bought a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) in a recent quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 2,614,012 sha…

ARCT −0.6% todayRead at source ↗
● Business WireAug 31, 2026 · 16:01 ET
Arcturus Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare dis…

ARCT −0.6% todayRead at source ↗
● Zacks Investment ResearchAug 27, 2026 · 10:55 ET
Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?

After reaching an important support level, Arcturus Therapeutics Holdings Inc. (ARCT) could be a good stock pick from a technical perspective. ARCT recently experienced a "golden cross" event, which saw its 50-day simple…

ARCT −0.6% todayRead at source ↗

No recent releases where the company itself is speaking.

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA7−4.1%
APP3+1.5%
BRK-A3−0.3%

Article counts from the last market-wide feed page, across every symbol we track and not just ARCT · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.